Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Brii Biosciences Ltd (2137) operate in?
Brii Biosciences Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Brii Biosciences Ltd (2137) current stock price?
As of the latest data, Brii Biosciences Ltd stock price is HK$0.98, with a previous close of HK$0.98.
What is Brii Biosciences Ltd (2137) current market capitalization?
Brii Biosciences Ltd market cap is approximately 707.22 million.
What is Brii Biosciences Ltd (2137) EBITDA?
Brii Biosciences Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -144.95 million.
Does Brii Biosciences Ltd (2137) pay dividends?
No. Brii Biosciences Ltd does not pay a dividend.
What is Brii Biosciences Ltd (2137) beta (volatility) score?
Brii Biosciences Ltd has a beta of 1.248, suggesting it is more volatile than the market.
